Suplatast tosilate
CAS No. 94055-76-2
Suplatast tosilate ( IPD-1151T )
产品货号. M16728 CAS No. 94055-76-2
一种 Th2 细胞因子抑制剂,可减弱 IL-2、IL-5 和 IL-13 的产生,但对 IFN-γ 的产生没有影响。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥117 | 有现货 |
|
| 10MG | ¥158 | 有现货 |
|
| 25MG | ¥237 | 有现货 |
|
| 50MG | ¥338 | 有现货 |
|
| 100MG | ¥521 | 有现货 |
|
| 200MG | ¥831 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥322 | 有现货 |
|
生物学信息
-
产品名称Suplatast tosilate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述一种 Th2 细胞因子抑制剂,可减弱 IL-2、IL-5 和 IL-13 的产生,但对 IFN-γ 的产生没有影响。
-
产品描述A Th2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production; suppresses IgE production, eosinophil infiltration and histamine release; exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.Allergy Approved(In Vitro):IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).(In Vivo):Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum.
-
体外实验IPD-1151T (1-10 μM; 10 d) induces a concentration-dependent suppression of purified allergen (Cry j 1)-dependent IgE synthesis in autologous B cell cultures mediated by SN-4, without significantly affecting the IgG synthesis.IPD-1151T (1-10 μM; 24 h) clearly depresses phytohemagglutinin (PHA)-induced expression of IL-4 mRNA in normal peripheral blood mononuclear cells (PBMC).
-
体内实验Suplatast Tosilate (100 mg/kg; once daily for 21 d) inhibits the production of Th2 cytokines, which inhibits eosinophil infiltration into the murine airway, IgE synthesis, and development of BHR, in a murine model of asthma.Suplatast Tosilate (100 μg/kg; once daily for 14 d) strongly suppresses immunoglobulin E contents in serum. Animal Model:Female BALB/c mice (6-8 weeks old) are immunized with ovalbuminDosage:100 mg/kg Administration:P.o. once a day for 21 days Result:Reduced the number of total cells and eosinophils.Almost completely inhibited the development of antigen-induced bronchial hyperresponsiveness (BHR).Decreased the levels of IL-4, IL-5 and IL-13.
-
同义词IPD-1151T
-
通路Apoptosis
-
靶点IL Receptor
-
受体Th2cytokine
-
研究领域Inflammation/Immunology
-
适应症Allergy
化学信息
-
CAS Number94055-76-2
-
分子量499.6406
-
分子式C23H33NO7S2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 33 mg/mL
-
SMILESCCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1
-
化学全称Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, 4-methylbenzenesulfonate (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Taniguchi H, et al. Eur J Pharmacol. 1996 Dec 30;318(2-3):447-54.
2. Konno S, et al. Eur J Pharmacol. 1994 Jun 23;259(1):15-20.
3. Furonaka M, et al. J Pharmacol Exp Ther. 2009 Jan;328(1):55-61.
产品手册
关联产品
-
SDZ 224-015
SDZ 224-015 是具有口服活性的、IL-1β 转化酶和 caspase-1 的抑制剂。SDZ 224-015 具有抗COVID-19的活性,靶向 Mpro (IC50 of 30 nM)。
-
IL-17A inhibitor 1
IL-17A抑制剂1(实施例24)是IL-17A的抑制剂。
-
Secukinumab B
Anti-Human IL-17A是一种全人抗白细胞介素 17A单克隆抗体。Anti-Human IL-17A可用于银屑病发病机制研究。
021-51111890
购物车()
sales@molnova.cn

